Malek E - Search Results

1

Novel therapies emerging in oncology to target the TGF-β pathway.

Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Kim BG, et al. Among authors: malek e. J Hematol Oncol. 2021 Apr 6;14(1):55. doi: 10.1186/s13045-021-01053-x. J Hematol Oncol. 2021. PMID: 33823905 Free PMC article. Review.

2

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators. Mateos MV, et al. Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18. Lancet Haematol. 2019. PMID: 31327687 Clinical Trial.

3

MicroRNAs in brain metastases: potential role as diagnostics and therapeutics.

Alsidawi S, Malek E, Driscoll JJ. Alsidawi S, et al. Among authors: malek e. Int J Mol Sci. 2014 Jun 11;15(6):10508-26. doi: 10.3390/ijms150610508. Int J Mol Sci. 2014. PMID: 24921708 Free PMC article. Review.

4

Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer.

Malek E, Jagannathan S, Driscoll JJ. Malek E, et al. Oncotarget. 2014 Sep 30;5(18):8027-38. doi: 10.18632/oncotarget.2469. Oncotarget. 2014. PMID: 25275300 Free PMC article. Review.

5

Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.

Jaganathan S, Malek E, Vallabhapurapu S, Vallabhapurapu S, Driscoll JJ. Jaganathan S, et al. Among authors: malek e. Oncotarget. 2014 Dec 15;5(23):12358-70. doi: 10.18632/oncotarget.2590. Oncotarget. 2014. PMID: 25481044 Free PMC article.

6

Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.

Abdel Malek MA, Jagannathan S, Malek E, Sayed DM, Elgammal SA, Abd El-Azeem HG, Thabet NM, Driscoll JJ. Abdel Malek MA, et al. Among authors: malek e. Oncotarget. 2015 Feb 20;6(5):3098-110. doi: 10.18632/oncotarget.3075. Oncotarget. 2015. PMID: 25605012 Free PMC article.

7

Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.

Jagannathan S, Abdel-Malek MA, Malek E, Vad N, Latif T, Anderson KC, Driscoll JJ. Jagannathan S, et al. Among authors: malek e. Leukemia. 2015 Nov;29(11):2184-91. doi: 10.1038/leu.2015.157. Epub 2015 Jun 25. Leukemia. 2015. PMID: 26108695 Free PMC article.

8

Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods.

Malek E, Sendilnathan A, Yellu M, Petersen A, Fernandez-Ulloa M, Driscoll JJ. Malek E, et al. Blood Cancer J. 2015 Jul 24;5(7):e326. doi: 10.1038/bcj.2015.51. Blood Cancer J. 2015. PMID: 26207787 Free PMC article. No abstract available.

9

Myeloid-derived suppressor cells: The green light for myeloma immune escape.

Malek E, de Lima M, Letterio JJ, Kim BG, Finke JH, Driscoll JJ, Giralt SA. Malek E, et al. Blood Rev. 2016 Sep;30(5):341-8. doi: 10.1016/j.blre.2016.04.002. Epub 2016 Apr 12. Blood Rev. 2016. PMID: 27132116 Free PMC article. Review.

10

High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.

Malek E, Driscoll JJ. Malek E, et al. Oncotarget. 2016 Jun 21;7(25):38523-38538. doi: 10.18632/oncotarget.9568. Oncotarget. 2016. PMID: 27229530 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page